Armata Pharmaceuticals (ARMP) Research & Development (2013 - 2026)
Armata Pharmaceuticals (ARMP) posted Research & Development of $6.1 million for Q1 2026, up 0.68% sequentially from $6.1 million in Q4 2025, and up 12.56% YoY from $5.4 million in Q1 2025.
Armata Pharmaceuticals (ARMP) Research & Development (2013 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Research & Development for 14 years, with the latest figure at $6.1 million in Q1 2026.
- Quarterly Research & Development rose 12.56% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.4 million (down 23.37% YoY) and the FY2025 annual result came in at $23.7 million, down 31.11% from the prior year.
- Research & Development advanced to $6.1 million in Q1 2026 per ARMP's latest filing, from $6.1 million in the prior quarter.
- Over five years, Research & Development peaked at $9.6 million in Q1 2023 and troughed at $5.4 million in Q1 2025.
- A 5-year average of $7.8 million and a median of $8.0 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development soared 98.77% in 2022, then slumped 38.6% in 2025.
- Over 5 years, Research & Development stood at $9.6 million in 2022, then declined by 17.15% to $7.9 million in 2023, then climbed by 6.6% to $8.5 million in 2024, then fell by 28.17% to $6.1 million in 2025, then climbed by 0.68% to $6.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $6.1 million, $6.1 million, and $5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Armata Pharmaceuticals | 162.98 Mn | 138.98 Mn | - | 7.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.59 Mn |
| Mar 31, 2026 | 6.11 Mn |
| Dec 31, 2025 | 6.07 Mn |
| Sep 30, 2025 | 5.82 Mn |
| Jun 30, 2025 | 6.39 Mn |
| Mar 31, 2025 | 5.43 Mn |
| Dec 31, 2024 | 8.45 Mn |
| Sep 30, 2024 | 9.49 Mn |
| Jun 30, 2024 | 8.48 Mn |
| Mar 31, 2024 | 8.02 Mn |
| Dec 31, 2023 | 7.93 Mn |
| Sep 30, 2023 | 7.98 Mn |
| Jun 30, 2023 | 8.26 Mn |
| Mar 31, 2023 | 9.60 Mn |
| Dec 31, 2022 | 9.57 Mn |
| Sep 30, 2022 | 8.40 Mn |
| Jun 30, 2022 | 9.02 Mn |
| Mar 31, 2022 | 8.03 Mn |
| Dec 31, 2021 | 4.81 Mn |
| Sep 30, 2021 | 5.63 Mn |